ARBs Under Development
Several new nonpeptide ARBs are undergoing clinical trials or are at pre-clinical stages of development. Among these are embusartan (BAY 10-6734 or BAY 10-6734), KRH-594, fonsartan (HR 720) and pratosartan (KT3-671). Pratosartan, for example, has a novel structure: a seven-membered ring that bears an oxo moiety (C=O) fused to the imidazole ring (figure 4), and its affinity for the AT1 receptor is about 7 times higher than losartan's. The purpose of the oxo group is similar to that of the carboxylic acid groups on other ARBs.
Other attributes of ARBs are also under investigation, such as the positive effects of telmisartan on lipid and glucose metabolism and losartan's effects of lowering uric acid levels. Such effects might lead to new indications for these drugs but further research is needed.
Read more about this topic: Discovery And Development Of Angiotensin Receptor Blockers
Famous quotes containing the word development:
“For the child whose impulsiveness is indulged, who retains his primitive-discharge mechanisms, is not only an ill-behaved child but a child whose intellectual development is slowed down. No matter how well he is endowed intellectually, if direct action and immediate gratification are the guiding principles of his behavior, there will be less incentive to develop the higher mental processes, to reason, to employ the imagination creatively. . . .”
—Selma H. Fraiberg (20th century)